Horizon Therapeutics PLC (NASDAQ:HZNP)

23.88
Delayed Data
As of Jun 25
 +0.60 / +2.58%
Today’s Change
15.92
Today|||52-Week Range
29.44
+22.21%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$4.4B

Company Description

Horizon Therapeutics Plc is a biopharmaceutical company which is engaged in the research, development and market of pharmaceutical products. The medicines intend to treat arthritis, inflammation and orphan diseases. It distributes its products under the brands such as Actimmune, Buphenyl, Duexis, Krystexxa, Migergot, Pennsaid, Ravicti, Rayos and Vimovo. The company was founded in 2008 and is headquartered in Dublin, Ireland.

Contact Information

Horizon Therapeutics Plc
Connaught House
Dublin Dublin 4
P:(531) 772-2100
Investor Relations:

Employees

Shareholders

Other institutional57.51%
Mutual fund holders33.83%
Individual stakeholders0.12%

Top Executives

Timothy P. WalbertChairman, President & Chief Executive Officer
Robert W. MetzSenior VP-Business Operations & Government Affairs
Paul W. HoelscherChief Financial Officer & Executive Vice President
Jeffrey D. KentSVP & Head-Medical Affairs & Outcomes Research
Michael A. DesJardinExecutive Vice President-Technical Operations